DBV Technologies appoints former US FDA chief counsel to board
This article was originally published in Clinica
DBV Technologies (Paris, France), a developer of non-invasive epicutaenous diagnostics and immunotherapies for allergies, has appointed Peter Barton Hutt as a non-executive director. Mr Hutt is currently a senior counsel at Covington & Burling law firm (Washington, DC) where he specialises in food and drug law – which he also teaches at Harvard Law School. A former chief counsel for the US FDA, Mr Hutt has first-hand experience of US FDA legislation. He is a member of the US Institute of Medicine.
You may also be interested in...
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.